CollabRx Debuts Cancer Genomics Service to Distinguish Itself from DTC Genomics Firms

The web-based CollabRx One program, which will charge cancer patients between $50,000 and $100,000 to generate genetically-targeted treatment options, compares 15,000 genes against tumor samples to gauge how they respond to as many as 5,000 drugs.

With the launch of CollabRx One, CollabRx hopes to advance the “discovery of new therapies by aggregating the learning from every patient.”

Connect With Us
Join other physicians who are receiving our updates.
We hate spam. Your email address will not be sold or shared with anyone else.